NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 13 October 2021

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien [Chair] Present for all items
2. Dr Peter Selby [Vice Chair] Present for all items
3. Dr Alex Cale Present for all items
4. Michael Chambers Items 1 to 3.2.2
5. Dr Prithwiraj Das Present for all items
6. Dr David Foreman Present for all items
7. Dr Rob Forsyth Present for all items
8. Dr Natalie Hallas Present for all items
9. Dr Nigel Langford Present for all items
10. Iain McGowan Present for all items
11. Kirandip Moyo Present for all items
12. Dr Mudasar Mushtaq Present for all items
13. Dr Richard Nicholas Present for all items
14. Ugochi Nwulu Items 4 to 4.2.2
15. Stella O’Brien Present for all items
16. Professor Subhash Pokhrel Present for all items
17. Professor Andrew Renehan Present for all items
18. Professor Matthew Stevenson Items 1 to 3.1.3
19. Professor Paul Tappenden Present for all items
20. Dr Derek Ward Present for all items

NICE staff present

Jasdeep Hayre, Associate Director Present for all items

Gavin Kenny, Project Manager Present for all items

Caron Jones, Health Technology Assessment Adviser Items 1 to 3.2.2

Alex Filby, Health Technology Assessment Adviser Items 4 to 4.2.2

Catherine Parker, Health Technology Assessment Analyst Items 1 to 3.2.2

Alan Moore, Health Technology Assessment Analyst Items 4 to 4.2.2

Benjamin Gregory, Business Analyst, RIA Present for all items

Korin Knight, Senior Medical Editor Items 1 to 3.2.2

Emilene Coventry, Senior Medical Editor Items 4 to 4.2.2

Ella Livingstone, Technical Adviser, Commercial Risk Assessment Items 1 to 3.2.2

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment Items 4 to 4.2.2

Laura Marsden, Public Involvement Adviser, PIP Present for all items

Rosalee Mason, Coordinator, Corporate Office Items 1 to 3.1.3 & 4 to 4.1.3

Gemma Smith, Coordinator, COT Present for all items

Ismahan Abdullah, Administrator, TA Present for all items

External review group representatives present

Nigel Armstrong, Kleijnen Systematic Reviews Ltd Items 1 to 3.1.3

Maiwenn Al, Kleijnen Systematic Reviews Ltd Items 1 to 3.1.3

Joanne Lord, Southampton Health Technology Assessment Centre [SHTAC]

Items 4 to 4.1.3

Jo Picot, Southampton Health Technology Assessment Centre [SHTAC]

Items 4 to 4.1.3

Experts present

Dr Sonya Craig, Consultant Sleep and Respiratory Physician, clinical expert nominated by the British Thoracic Society, Items 1 to 3.1.3

Graham Hill, Patient expert, nominated by the Sleep Apnoea Trust Association, Items 1 to 3.1.3

Dr Ari Manuel, Consultant in sleep medicine, clinical expert nominated by Lincoln Medical, Items 1 to 3.1.3

Dr Adrian Williams, Consultant Physician, clinical expert nominated by nominated by Jazz Pharmaceuticals, Items 1 to 3.1.3

Dr Sofia Eriksson, Consultant Neurologist, Clinical expert nominated by Association of British Neurologists, Items 4 to 4.1.3

Matt O’Neil, Patient expert nominated by Narcolepsy UK, Items 4 to 4.1.3

Helen Strongman, Patient expert nominated by Narcolepsy UK, Items 4 to 4.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Appraisal of pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1065]

* 1. Part 1 – Open session
		1. The chair Professor Stephen O’Brien welcomed the invited clinical and patient experts, external review group representatives, members of the public and company representatives from Bioprojet.
		2. The chair asked all committee members, clinical and patient experts, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has provided consultancy advice to Shire Pharmaceuticals in disease areas in an unrelated area, most recently in late 2017. Shire is part of Takeda Pharmaceuticals, with whom he currently has a long-term contract to undertake activities in EU Innovative Medicines Initiative [IMI] projects, again in an unrelated area of this appraisal.
* It was agreed that his declaration would not prevent Mr Chambers from participating in this section of the meeting.
* Dr Richard Nicholas declared financial interests as he has been paid advisory boards for Novartis for treatments in an unrelated area [MS].
* It was agreed that his declaration would not prevent Dr Nicholas from participating in this section of the meeting.
* Nominated clinical expert Dr Sonya Craig declared non-financial interests as she is sitting on an advisory board for pitolisant which is another drug for excessive daytime sleepiness and has attended the ERS conference in Madrid 2019 paid for by Bioprojet who make pitolisant, she confirmed she had received no payment.
* It was agreed that her declaration would not prevent Dr Craig from providing expert advice to the committee.
* Nominated clinical expert Dr Ari Manuel declared a financial interest as he has provided a lecture for Lincoln Medical on the pathophysiology of OSA in April 2020 and was paid £400.
* It was agreed that his declaration would not prevent Dr Manuel from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session [company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting]
		1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD] in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10385>

### Appraisal of solriamfetol for treating excessive daytime sleepiness caused by narcolepsy [ID1602]

* 1. Part 1 – Open session
		1. The chair welcomed the invited clinical and patient experts, external review group representatives, members of the public and company representatives from Jazz Pharmaceuticals.
		2. The chair asked all committee members, clinical and patient experts, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Richard Nicholas declared a financial interest as he has attended paid advisory boards for Novartis in an unrelated area.
* It was agreed that his declaration would not prevent Dr Nicholas from participating in this section of the meeting.
* Nominated patient expert Matt O’Neill declared a financial interest as he has received speaker and advisory board fees from Lincoln Medical Ltd, Takeda UK & UCB Pharma UK and has received grants/honoraria from Avadel, Lincoln Medical Ltd, UCB Pharma UK & Jazz Pharma Ltd. Matt confirmed all fees are paid to Narcolepsy UK & all his time is provided on a voluntary basis only.
* It was agreed that his declaration would not prevent Matt from providing expert advice to the committee.
* Nominated clinical expert Dr Sofia Eriksson declared a non-financial interest as she has received honoraria for educational activities and conference attendance from, UCB Pharma, Bioprojet, Eisai, and Fidia Pharma. Sofia confirmed none were received after November 2019.
* It was agreed that her declaration would not prevent Sofia from providing expert advice to the committee.
* Nominated patient expert Helen Strongman declared non-financial interests as she is Trustee at Narcolepsy UK and Assistant Professor at the London School of Hygiene & Tropical Medicine.
* It was agreed that her declaration would not prevent Helen from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session [company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting].
		1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10524>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 9 November 2021 and will start promptly at 9.30am.